Sugi Predict

Sugi Predict / Compounds / SCHEMBL934418

SCHEMBL934418

SCHEMBL934418

N#Cc1cc(N)c(F)cc1F

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 3/20 0.50
▸ KHK P50053 1/20 0.42
▸ CYP11B2 P19099 10/20 0.40
▸ CYP11B1 P15538 9/20 0.40
▸ KDM4E B2RXH2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ EGLN2 Q96KS0 3/20 0.36
▸ ADRB2 P07550 1/20 0.35
▸ ADRB1 P08588 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29467996 1.00 TRPV4 (0.50) TRPV4KHKCYP11B2CYP11B1KDM4E
SCHEMBL332547 0.91 TRPV4 (0.56) TRPV4KHKCYP11B2CYP11B1KDM4E
SCHEMBL2314240 0.88 TRPV4 (0.52) TRPV4KHKCYP11B2CYP11B1KDM4E
SCHEMBL13660126 0.88 KHK (0.48) TRPV4KHKCYP11B2CYP11B1KDM4E
SCHEMBL9489932 0.82 TRPV4 (0.61) TRPV4KHKCYP11B2CYP11B1
SCHEMBL6661759 0.81 KHK (0.47) TRPV4KHKCYP11B2CYP11B1KDM4E
SCHEMBL24636078 0.80 KHK (0.39) TRPV4KHKCYP11B2CYP11B1KDM4E
SCHEMBL15769482 0.80 KHK (0.39) TRPV4KHKCYP11B2CYP11B1KDM4E
SCHEMBL17559551 0.80 KHK (0.47) TRPV4KHKCYP11B2CYP11B1KDM4E
SCHEMBL30868453 0.80 KHK (0.39) TRPV4KHKCYP11B2CYP11B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179072-A1 TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2025-06-05 — — US disclosed
WO-2025108301-A1 FURAN RING-CONTAINING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 武汉熙瑞医药科技有限公司 2025-05-30 — — WO disclosed
US-20240262827-A1 TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2024-08-08 — — US disclosed
US-11970497-B2 Tricyclic AKR1C3 dependent KARS inhibitors NOVARTIS AG (CH) 2024-04-30 — — US disclosed
EP-4349839-A2 TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS Novartis AG (CH) 2024-04-10 — — EP disclosed
CN-115427412-B Nitrogen-containing fused ring derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-02-20 — — CN disclosed
EP-4013500-B1 TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS NOVARTIS AG (CH) 2023-10-25 — — EP disclosed
WO-2023169547-A1 DNA POLYMERASE θ INHIBITOR AND USE THEREOF 四川海思科制药有限公司 2023-09-14 — — WO disclosed
US-20230271969-A1 NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-08-31 — — US disclosed
US-20230271969-A1 NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-08-31 — — US disclosed
US-20120115869-A1 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2012-05-10 — — US disclosed
US-20120115869-A1 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2012-05-10 — — US disclosed
US-20120115869-A1 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2012-05-10 — — US disclosed
US-7902183-B2 Thiazolyl-dihydro-indazole BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-08 — — US disclosed
WO-2011006935-A2 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2011-01-20 — — WO disclosed
WO-2011006935-A2 TETRAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2011-01-20 — — WO disclosed
CN-101443335-A Thiazolyl dihydro-indazoles BOEHRINGER INGELHEIM INT (DE) 2009-05-27 — — CN disclosed
EP-2007773-A1 THIAZOLYL DIHYDRO-INDAZOLES Boehringer Ingelheim International GmbH (DE) 2008-12-31 — — EP disclosed
US-20070270401-A1 Thiazolyl-Dihydro-Indazole BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-22 — — US disclosed
WO-2007113245-A1 THIAZOLYL DIHYDRO-INDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270401-A1 Thiazolyl-Dihydro-Indazole MKI67, INSR, CCNT1 TRPV4 2667/4885KHK 2011/4885CYP11B2 8/4885
US-20120115869-A1 TETRAZOLE DERIVATIVES TSLP, IL5, CMA1 TRPV4 214/4885KHK 2448/4885CYP11B2 159/4885
US-20250179072-A1 TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS AKR1C2, AKR1B1, AKR1C1 TRPV4 3597/4885KHK 43/4885CYP11B2 47/4885
US-11970497-B2 Tricyclic AKR1C3 dependent KARS inhibitors AKR1C2, AKR1B1, AKR1C1 TRPV4 3597/4885KHK 43/4885CYP11B2 47/4885
US-20230271969-A1 NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF NR5A1, WEE1, SHBG TRPV4 4865/4885KHK 1259/4885CYP11B2 21/4885
US-20240262827-A1 TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS AKR1C2, AKR1B1, AKR1C1 TRPV4 3597/4885KHK 43/4885CYP11B2 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.